Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015695 (
fatty liver
)
13,941
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The activities of
coproporphyrinogen oxidase
, protoporphyrinogen oxidase and ferrochelatase have been assayed in human liver biopsies using recently developed highly sensitive specific enzyme assays. The specific activities (nmol/min/mg protein) in controls were 0.010 +/- 0.003 (mean +/- S.D., n = 11), 0.18 +/- 0.07 (n = 9) and 0.062 +/- 0.022 (n = 8), respectively. The total activities (mumol/min/liver) were determined, using ultrasound to determine liver volumes, and were 2.6 +/- 0.6 (n = 5), 36.6 +/- 13.9 (n = 6) and 14.2 +/- 5.4 (n = 3), respectively. Both specific and total enzyme activities in alcoholics with
fatty liver
were not significantly different from normal controls. Decreased protoporphyrinogen oxidase activity (0.08 nmol/min/mg protein or 20.2 mumol/min/liver) was found in two patients with variegate porphyria. In a patient with erythrohepatic protoporphyria a reduction of the ferrochelatase activity (0.01 nmol/min/mg protein) was demonstrated.
...
PMID:Coproporphyrinogen oxidase, protoporphyrinogen oxidase and ferrochelatase activities in human liver biopsies with special reference to alcoholic liver disease. 292 8